The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Radiopharmaceuticals in Nuclear Medicine Market Research Report 2024
Synopsis
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceuticals in Nuclear Medicine market was valued at US$ 4804.6 million in 2023 and is anticipated to reach US$ 6988.2 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals in Nuclear Medicine.
Report Scope
The Radiopharmaceuticals in Nuclear Medicine market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radiopharmaceuticals in Nuclear Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceuticals in Nuclear Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases. Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
The global Radiopharmaceuticals in Nuclear Medicine market was valued at US$ 4804.6 million in 2023 and is anticipated to reach US$ 6988.2 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Radiopharmaceuticals in Nuclear Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Radiopharmaceuticals in Nuclear Medicine.
Report Scope
The Radiopharmaceuticals in Nuclear Medicine market size, estimations, and forecasts are provided in terms of sales volume (K MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Radiopharmaceuticals in Nuclear Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Radiopharmaceuticals in Nuclear Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bracco Imaging S.P.A.
Cambridge Isotope Laboratories, Inc.
Cardinal Health, Inc.
Covidien, Plc
Eczacibasi-Monrol
Fujifilm Holdings Corporation
GE Healthcare (Subsidiary Of General Electric Company)
IBA Group
Isotec, Inc. (Sigma-Aldrich)
Lantheus Medical Imaging, Inc.
Nordion, Inc.
Ntp Radioisotopes (Pty), Ltd.
Siemens Healthcare (Subsidiary Of Siemens AG)
Taiyo Nippon Sanso Corporation
Urenco Limited
Rotem Industries, Ltd., Inc.
Australian Nuclear Association And Technology Organization (ANSTO)
Board of Radiation And Isotope Technology (BRIT)
Institute of Atomic Energy Polatom Radioisotope Centre
Institute of Isotopes Co., Ltd.
Institute Of Radioelement (IRE)
Segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Enriched Stable Isotopes
Segment by Application
Diagnostic Application
Therapeutic Application
Research
Pharmaceutical
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Radiopharmaceuticals in Nuclear Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Radiopharmaceuticals in Nuclear Medicine Market Overview
1.1 Product Overview and Scope of Radiopharmaceuticals in Nuclear Medicine
1.2 Radiopharmaceuticals in Nuclear Medicine Segment by Type
1.2.1 Global Radiopharmaceuticals in Nuclear Medicine Market Value Comparison by Type (2024-2030)
1.2.2 Diagnostic Radiopharmaceuticals
1.2.3 Therapy Radiopharmaceuticals
1.2.4 Enriched Stable Isotopes
1.3 Radiopharmaceuticals in Nuclear Medicine Segment by Application
1.3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Value by Application: (2024-2030)
1.3.2 Diagnostic Application
1.3.3 Therapeutic Application
1.3.4 Research
1.3.5 Pharmaceutical
1.3.6 Other
1.4 Global Radiopharmaceuticals in Nuclear Medicine Market Size Estimates and Forecasts
1.4.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue 2019-2030
1.4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales 2019-2030
1.4.3 Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Radiopharmaceuticals in Nuclear Medicine Market Competition by Manufacturers
2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Radiopharmaceuticals in Nuclear Medicine Average Price by Manufacturers (2019-2024)
2.4 Global Radiopharmaceuticals in Nuclear Medicine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Radiopharmaceuticals in Nuclear Medicine, Product Type & Application
2.7 Radiopharmaceuticals in Nuclear Medicine Market Competitive Situation and Trends
2.7.1 Radiopharmaceuticals in Nuclear Medicine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue
2.7.3 Global Radiopharmaceuticals in Nuclear Medicine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Radiopharmaceuticals in Nuclear Medicine Retrospective Market Scenario by Region
3.1 Global Radiopharmaceuticals in Nuclear Medicine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Radiopharmaceuticals in Nuclear Medicine Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2019-2030
3.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2019-2024
3.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2025-2030
3.3 Global Radiopharmaceuticals in Nuclear Medicine Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2019-2030
3.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2019-2024
3.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2025-2030
3.4 North America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.4.1 North America Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2030)
3.4.3 North America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.5.1 Europe Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2030)
3.5.3 Europe Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.6.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2030)
3.6.3 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.7.1 Latin America Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2030)
3.7.3 Latin America Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Facts & Figures by Country
3.8.1 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2019-2030)
4.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2019-2024)
4.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2025-2030)
4.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2019-2030)
4.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2019-2030)
4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2019-2024)
4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2025-2030)
4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2019-2030)
4.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2019-2030)
5.1.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2019-2024)
5.1.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2025-2030)
5.1.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2019-2030)
5.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2019-2030)
5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2019-2024)
5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2025-2030)
5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2019-2030)
5.3 Global Radiopharmaceuticals in Nuclear Medicine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bracco Imaging S.P.A.
6.1.1 Bracco Imaging S.P.A. Corporation Information
6.1.2 Bracco Imaging S.P.A. Description and Business Overview
6.1.3 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bracco Imaging S.P.A. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.1.5 Bracco Imaging S.P.A. Recent Developments/Updates
6.2 Cambridge Isotope Laboratories, Inc.
6.2.1 Cambridge Isotope Laboratories, Inc. Corporation Information
6.2.2 Cambridge Isotope Laboratories, Inc. Description and Business Overview
6.2.3 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Cambridge Isotope Laboratories, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.2.5 Cambridge Isotope Laboratories, Inc. Recent Developments/Updates
6.3 Cardinal Health, Inc.
6.3.1 Cardinal Health, Inc. Corporation Information
6.3.2 Cardinal Health, Inc. Description and Business Overview
6.3.3 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Cardinal Health, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.3.5 Cardinal Health, Inc. Recent Developments/Updates
6.4 Covidien, Plc
6.4.1 Covidien, Plc Corporation Information
6.4.2 Covidien, Plc Description and Business Overview
6.4.3 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Covidien, Plc Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.4.5 Covidien, Plc Recent Developments/Updates
6.5 Eczacibasi-Monrol
6.5.1 Eczacibasi-Monrol Corporation Information
6.5.2 Eczacibasi-Monrol Description and Business Overview
6.5.3 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Eczacibasi-Monrol Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.5.5 Eczacibasi-Monrol Recent Developments/Updates
6.6 Fujifilm Holdings Corporation
6.6.1 Fujifilm Holdings Corporation Corporation Information
6.6.2 Fujifilm Holdings Corporation Description and Business Overview
6.6.3 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Fujifilm Holdings Corporation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.6.5 Fujifilm Holdings Corporation Recent Developments/Updates
6.7 GE Healthcare (Subsidiary Of General Electric Company)
6.6.1 GE Healthcare (Subsidiary Of General Electric Company) Corporation Information
6.6.2 GE Healthcare (Subsidiary Of General Electric Company) Description and Business Overview
6.6.3 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GE Healthcare (Subsidiary Of General Electric Company) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.7.5 GE Healthcare (Subsidiary Of General Electric Company) Recent Developments/Updates
6.8 IBA Group
6.8.1 IBA Group Corporation Information
6.8.2 IBA Group Description and Business Overview
6.8.3 IBA Group Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 IBA Group Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.8.5 IBA Group Recent Developments/Updates
6.9 Isotec, Inc. (Sigma-Aldrich)
6.9.1 Isotec, Inc. (Sigma-Aldrich) Corporation Information
6.9.2 Isotec, Inc. (Sigma-Aldrich) Description and Business Overview
6.9.3 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Isotec, Inc. (Sigma-Aldrich) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.9.5 Isotec, Inc. (Sigma-Aldrich) Recent Developments/Updates
6.10 Lantheus Medical Imaging, Inc.
6.10.1 Lantheus Medical Imaging, Inc. Corporation Information
6.10.2 Lantheus Medical Imaging, Inc. Description and Business Overview
6.10.3 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Lantheus Medical Imaging, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.10.5 Lantheus Medical Imaging, Inc. Recent Developments/Updates
6.11 Nordion, Inc.
6.11.1 Nordion, Inc. Corporation Information
6.11.2 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.11.3 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Nordion, Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.11.5 Nordion, Inc. Recent Developments/Updates
6.12 Ntp Radioisotopes (Pty), Ltd.
6.12.1 Ntp Radioisotopes (Pty), Ltd. Corporation Information
6.12.2 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.12.3 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Ntp Radioisotopes (Pty), Ltd. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.12.5 Ntp Radioisotopes (Pty), Ltd. Recent Developments/Updates
6.13 Siemens Healthcare (Subsidiary Of Siemens AG)
6.13.1 Siemens Healthcare (Subsidiary Of Siemens AG) Corporation Information
6.13.2 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.13.3 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Siemens Healthcare (Subsidiary Of Siemens AG) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.13.5 Siemens Healthcare (Subsidiary Of Siemens AG) Recent Developments/Updates
6.14 Taiyo Nippon Sanso Corporation
6.14.1 Taiyo Nippon Sanso Corporation Corporation Information
6.14.2 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.14.3 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Taiyo Nippon Sanso Corporation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.14.5 Taiyo Nippon Sanso Corporation Recent Developments/Updates
6.15 Urenco Limited
6.15.1 Urenco Limited Corporation Information
6.15.2 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.15.3 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Urenco Limited Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.15.5 Urenco Limited Recent Developments/Updates
6.16 Rotem Industries, Ltd., Inc.
6.16.1 Rotem Industries, Ltd., Inc. Corporation Information
6.16.2 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.16.3 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Rotem Industries, Ltd., Inc. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.16.5 Rotem Industries, Ltd., Inc. Recent Developments/Updates
6.17 Australian Nuclear Association And Technology Organization (ANSTO)
6.17.1 Australian Nuclear Association And Technology Organization (ANSTO) Corporation Information
6.17.2 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.17.3 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Australian Nuclear Association And Technology Organization (ANSTO) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.17.5 Australian Nuclear Association And Technology Organization (ANSTO) Recent Developments/Updates
6.18 Board of Radiation And Isotope Technology (BRIT)
6.18.1 Board of Radiation And Isotope Technology (BRIT) Corporation Information
6.18.2 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.18.3 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Board of Radiation And Isotope Technology (BRIT) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.18.5 Board of Radiation And Isotope Technology (BRIT) Recent Developments/Updates
6.19 Institute of Atomic Energy Polatom Radioisotope Centre
6.19.1 Institute of Atomic Energy Polatom Radioisotope Centre Corporation Information
6.19.2 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.19.3 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Institute of Atomic Energy Polatom Radioisotope Centre Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.19.5 Institute of Atomic Energy Polatom Radioisotope Centre Recent Developments/Updates
6.20 Institute of Isotopes Co., Ltd.
6.20.1 Institute of Isotopes Co., Ltd. Corporation Information
6.20.2 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.20.3 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Institute of Isotopes Co., Ltd. Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.20.5 Institute of Isotopes Co., Ltd. Recent Developments/Updates
6.21 Institute Of Radioelement (IRE)
6.21.1 Institute Of Radioelement (IRE) Corporation Information
6.21.2 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Description and Business Overview
6.21.3 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Institute Of Radioelement (IRE) Radiopharmaceuticals in Nuclear Medicine Product Portfolio
6.21.5 Institute Of Radioelement (IRE) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radiopharmaceuticals in Nuclear Medicine Industry Chain Analysis
7.2 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
7.4 Radiopharmaceuticals in Nuclear Medicine Sales and Marketing
7.4.1 Radiopharmaceuticals in Nuclear Medicine Sales Channels
7.4.2 Radiopharmaceuticals in Nuclear Medicine Distributors
7.5 Radiopharmaceuticals in Nuclear Medicine Customers
8 Radiopharmaceuticals in Nuclear Medicine Market Dynamics
8.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
8.2 Radiopharmaceuticals in Nuclear Medicine Market Drivers
8.3 Radiopharmaceuticals in Nuclear Medicine Market Challenges
8.4 Radiopharmaceuticals in Nuclear Medicine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
